Hospital
Henderson County Hospital Corporation
Henderson County Hospital Corporation was paid $5.32M by Medicaid between Jan 2018 and Dec 2024, across 92 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoHENDERSON COUNTY HOSPITAL CORPORATION
HENDERSONVILLE, NC 28791
HENDERSONVILLE, NC 28791
33aNPI1144247982assigned 07/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.32M
24GClaims130,501
24DCodes billed92
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#62 of 92
Median peer was paid$11.47M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,059 | $771K | |
| 2019 | 19,772 | $631K | |
| 2020 | 13,701 | $245K | |
| 2021 | 16,325 | $598K | |
| 2022 | 16,160 | $770K | |
| 2023 | 20,634 | $1.08M | |
| 2024incomplete | 21,850 | $1.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 10,746 | 10,327 | $1.42M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 6,882 | 6,588 | $1.28M |
| 41899 | Unlisted procedure, dentoalveolar structures | 17% | 275 | 264 | $894K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 15% | 40,642 | 36,638 | $815K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.1% | 1,028 | 993 | $164K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.6% | 420 | 408 | $139K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 14,300 | 12,162 | $87K |
| 80053 | Comprehensive metabolic panel | 1.5% | 11,207 | 10,226 | $81K |
| J3490 | Unclassified drugs | 1.4% | 16,698 | 9,654 | $72K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,748 | 1,620 | $38K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 372 | 355 | $31K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 711 | 682 | $26K |
80 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 301 | $22K |
| 81003 | <1% | 5,457 | $16K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 12 | $15K |
| 71045 | Radiologic examination, chest; single view | <1% | 343 | $14K |
| 97597 | <1% | 441 | $14K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 342 | $12K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 139 | $12K |
| 81001 | <1% | 3,911 | $11K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 51 | $11K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 804 | $10K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 43 | $9K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 17 | $9K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 28 | $9K |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,024 | $8K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 769 | $7K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 313 | $7K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,582 | $7K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 713 | $7K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 95 | $5K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 473 | $5K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 31 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 280 | $4K |
| 83735 | <1% | 741 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 81 | $4K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 39 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 211 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 312 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 97 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 53 | $2K |
| 85027 | <1% | 252 | $2K | |
| 73610 | <1% | 41 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 366 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 145 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 98 | $2K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 16 | $2K |
| 81025 | <1% | 207 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 34 | $1K |
| 73030 | <1% | 27 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 313 | $1K |
| 83690 | <1% | 178 | $1K | |
| 73630 | <1% | 14 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 26 | $1K |
| 97016 | <1% | 134 | $1K | |
| 83655 | <1% | 59 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 31 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 31 | $1K |
| 97803 | <1% | 52 | $781.45 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 38 | $702.58 |
| 84484 | <1% | 76 | $647.50 | |
| 82607 | <1% | 26 | $643.23 | |
| 82746 | <1% | 26 | $627.53 | |
| 73140 | <1% | 13 | $600.34 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 66 | $573.29 |
| 85652 | <1% | 196 | $507.93 | |
| 81002 | <1% | 113 | $463.46 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 160 | $424.78 |
| 86140 | <1% | 89 | $407.50 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 38 | $406.20 |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 48 | $375.48 |
| 80061 | Lipid panel | <1% | 29 | $367.40 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 151 | $357.55 |
| 73562 | <1% | 13 | $341.36 | |
| 20610 | <1% | 16 | $283.31 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 43 | $280.99 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 53 | $226.22 |
| 85651 | <1% | 69 | $216.95 | |
| 90686 | <1% | 105 | $213.46 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 24 | $209.57 |
| 86592 | <1% | 42 | $201.78 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 15 | $200.82 |
| 83540 | <1% | 26 | $193.98 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 27 | $132.99 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 42 | $119.98 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 16 | $77.52 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13 | $45.24 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 25 | $21.62 |
| 82962 | <1% | 15 | $17.52 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 41 | $0.65 |
| A9270 | Non-covered item or service | <1% | 79 | $0.19 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKIRBY, JAMES (PRESIDENT, CEO)
| Provider | Location | Paid |
|---|---|---|
| Henderson County Hospital Corporation | Hendersonville, NC | $2.93M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.